TY - JOUR T1 - Epidermal growth factor, innovation and safety JO - Medicina ClĂ­nica (English Edition) T2 - AU - Esquirol Caussa,Jordi AU - Herrero Vila,Elisabeth SN - 23870206 M3 - 10.1016/j.medcle.2016.02.028 DO - 10.1016/j.medcle.2016.02.028 UR - https://www.elsevier.es/en-revista-medicina-clinica-english-edition--462-articulo-epidermal-growth-factor-innovation-safety-S2387020616000930 AB - Bioidentical recombinant human epidermal growth factor (rhEGF) is available in concentrations and purity suitable for therapeutic use in long time stable formulations. Beneficial effects in several skin pathologies and lesions have been reported (traumatic and surgical wound healing, laser induced wounds, abnormal scars, keloids, radiation or chemotherapy induced dermatitis, post inflammatory hyperpigmentation or for skin aging damage repairing) and also may be considered for the treatment of several oropharingeal and high gastroesophageal tract mucosa diseases (mouth sores, pharyngeal fistulas, ulcers), and several corneal or conjunctive mucosa lesions.rhEGF has not shown any important side or collateral effects in humans or in laboratory experimentation animals, showing optimal tolerability and safety with continuous use for months.Compounding gives advantages of versatility, individualization, personalization, molecular stability, safety and effectiveness in ideal conditions, showing good tissue penetration, both on intact skin and skin lesions that expose the lower planes to the surface.rhEGF compounds can be considered for prevention or as a treatment of diverse skin and mucosa diseases and conditions through compounding preparations. ER -